Unambiguous Science

the user has only 57 posts

Myocarditis After mRNA Vaccines

Myocarditis collab with my friend Dr. Elisabeth Marnik. We have summarized all the info that is available thus far on the risk of myocarditis and pericarditis with the mRNA vaccines per CDC ACIP’s briefing this week. This far, the CDC maintains that the benefits outweigh the risks. We will continue to update as more information

Mixing AstraZeneca and mRNA Vaccines

1/ Protection after two doses The most important decision is to get second dose: stronger + longer lasting protection. Two doses of AZ effective at preventing serious illness from OG Covid-19 + early variants. Early studies show good immune response when Moderna/Pfizer used as second dose. 2/ Protection against new variants Delta variant spreading quickly.

What’s in a number? Let’s discuss vaccine efficacy.

What exactly is vaccine efficacy? Efficacy is a measure of how well a vaccine works in clinical trials – specifically, the percent reduction of disease by comparing two groups – one that receives the vaccine and one that doesn’t, under favourable and tightly controlled settings. However, how one measures efficacy can vary significantly. Within the

NACI AstraZeneca Guidance – Suspend Use in Younger Than Age 55

Small increased risk of rare types of blood clots accompanied with thrombocytopenia (low platelets). Called ‘vaccine-induced prothrombotic immune thrombocytopenia’ or VIPIT. VIPIT is very rare. Initial estimates from Germany were 4 per million. Subsequent Norwegian estimates are 42 per million. Per Science Table estimates: occurring in anywhere from 1 in every 125,000 to 1 in